Tildrakizumab 200 mg. Is double dosing really a window of opportunity?

Otros usuarios también vieron estos artículos

52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience F.J. Melgosa Ramos, A. Mateu Puchades, J. Matáix-Díaz, L. Schneller-Pavelescu, I. Belinchón-Romero, S. Santos Alarcón

10.1016/j.ad.2023.08.019

Can We Improve Prognosis in Hidradenitis Suppurativa? Identifying Patients in the Window of Opportunity F.J. Melgosa Ramos, R. García-Ruiz, A. Mateu Puchades, A. Martorell

10.1016/j.ad.2023.11.012

RF – Resistance to Permethrin in Scabies Treatment: Does It Really Exist? J.P. Velasco-Amador, A. Prados-Carmona, R. Ruiz-Villaverde

10.1016/j.ad.2022.05.046